February 7, 2017 – Philadelphia, PA
Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease.
February 7, 2017 – Philadelphia, PA
Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease.